AMLX
Amylyx Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
28.86
close · 2026-10-30
value
19
cheaper than peers19
quality
51
stronger fundamentals51
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | 2.4% | 76 |
| cash flow yield, 2 years ago | 0.3% | 45 |
| cash flow yield, 3 years ago | -5.0% | 35 |
| earnings yield, 3 years ago | -11.7% | 31 |
| earnings yield, latest year | -5.3% | 28 |
| cash flow yield, latest year | -3.4% | 26 |
| cash flow yield, 1 year ago | -4.6% | 26 |
| price to book | 13.44× | 19 |
| earnings yield, 1 year ago | -15.3% | 18 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 2.1% | 96 |
| operating margin | 0.0% | 41 |
| return on equity | -63.3% | 16 |
3 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$71.5M |
| employees | 136 |
| first trade | 2022-01-07 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.53 | -4.43 | 0.70 | -3.39 |
| free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M |
| net income | -$144.7M | -$301.7M | $49.3M | -$198.4M |
| revenue | $0 | $87.4M | $380.8M | $22.2M |
| unusual items | $0 | -$59.1M | $0 | not reported |